 In-PharmaTechnologist.com |
Lonza Reaffirms Commitment to Teva Biosimilars JV in Light of ‘Inaccurate …
In-PharmaTechnologist.com News of the strategy review follows a few months after Teva halted a Phase III trial of TL011 , a biosimilar version of Swiss drugmaker Roche’s Rituxan/MabThera (rituximab). According to a report in Israeli newspaper Haaretz at the time development was … |
|
Biogen Idec completa la adquisición de todos los derechos y control de TYSABRI®
Lainformacion.com Biogen Idec también cuenta con la cartera de EM más completa del sector con compuestos que incluyen PLEGRIDY (peginterferón beta-1a); el proceso de alto rendimiento de daclizumab (DAC HYP) para la administración subcutánea mensual; y un estudio … |
|
Omeros Announces Positive OMS721 Data in Model of Thrombotic …
PipelineReview.com (press release) SEATTLE, WA, USA I April 2, 2013 I Omeros Corporation (OMER) today announced positive data using OMS721, the lead human monoclonal antibody in Omeros’ mannan-binding lectin-associated serine protease-2 (MASP-2) program, in a well-established … |
|
Biogen Idec erwirbt umfassende Rechte an TYSABRI®
Finanzen.net Des Weiteren verfügt Biogen Idec über die branchenweit tiefstgreifende MS-Pipeline mit Wirkstoffen wie PLEGRIDY™ (Peginterferon Beta-1a), Daclizumab High-Yield Process (DAC HYP) für monatliche subkutane Verabreichung und eine laufende klinische … |
Biosimilars Could Be An Unlikely Boost For PfizerSeeking AlphaIn this same earnings call Pfizer CEO also mentions that they are working on 3 other biosimilars but they are not nearly as far along on those molecules as Trastuzumab and Rituximab. As an i…
|
Biogen Idec finalise l’achat de l’intégralité des droits et du contrôle de TYSABRI®
InformationHospitaliere.com Biogen Idec possède également le portefeuille le plus étendu du secteur pour la SEP avec des composés tels que le PLEGRIDY™ (peginterféron bêta-1a) ; le processus à haut rendement du daclizumab (DAC HYP) pour une administration sous-cutanée … |
|
Biogen Idec completa l’acquisto di tutti i diritti e ottiene il pieno controllo di …
ANSA.it Nel nostro settore industriale, Biogen Idec ha inoltre la pipeline più approfondita del settore per la SM, con composti che comprendono PLEGRIDY™ (peginterferone beta-1a); il processo ad alto rendimento Daclizumab (DAC HYP) per la somministrazione … |
|
Biogen Idec Completes Purchase of Full Rights and Control of TYSABRI®
PharmiWeb.com (press release) … three principal products AVONEX® (interferon beta-1a) TYSABRI and RITUXAN® (rituximab) the importance of TYSABRI’s sales growth uncertainty of success in commercializing and developing other products product competition the occurrence of adverse … |
|
Biogen acquires TYSABRI stake from Elan
News-Medical.net Biogen Idec also has the deepest MS pipeline in the industry with compounds that include PLEGRIDY™ (peginterferon beta-1a); daclizumab high-yield process (DAC HYP) for monthly subcutaneous administration; and an ongoing study with TYSABRI as a … |
Zee NewsHow antibodies neutralise chikungunya virusZee NewsHow antibodies neutralise chikungunya virus Washington: Researchers have been able to learn the precise structure of the mosquito-transmitted chikungunya virus pathogen while it is bound to ant…